WHO has updated its living guidelines on COVID-19 therapeutics. The ninth update released on 03 March 2022 include a conditional recommendation on molnupiravir.
Molnupiravir has...
Molnupiravir, the world’s first oral drug (approved by MHRA, UK) against COVID-19 along with upcoming drugs such as Paxlovid and sustained vaccination drive has raised hopes...
Molnupiravir, a nucleoside analog of cytidine, a drug that has shown excellent oral bioavailability and promising results in Phase 1 and Phase 2 trials, could prove...